Posted by Michael Wonder on 07 Oct 2020
Eli Lilly asks FDA to authorise COVID-19 antibody drug
7 October 2020 - Company says it could supply one million doses of the treatment this year, if regulator authorises emergency use.
Eli Lilly said it has requested U.S. authorisation of the emergency use of an experimental antibody-based treatment for people with recently diagnosed, mild-to-moderate COVID-19, following positive results from clinical testing.
The Indianapolis-based company said it is seeking the authorisation for its drug, code named LY-CoV555, which was derived from a blood sample of one of the earliest U.S. survivors of COVID-19.
